De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Ajanta Pharma Inkomsten in het verleden
Verleden criteriumcontroles 6/6
Ajanta Pharma is de winst gegroeid met een gemiddeld jaarlijks percentage van 11%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 15.2%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 12.9% per jaar. Het rendement op eigen vermogen van Ajanta Pharma is 23.9%, en het heeft een nettomarge van 19.7%.
Belangrijke informatie
11.0%
Groei van de winst
11.9%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.5% |
| Inkomstengroei | 12.9% |
| Rendement op eigen vermogen | 23.9% |
| Nettomarge | 19.7% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Sep 10
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Aug 23Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 04Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E
Aug 01With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
Jun 01Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results
May 05Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price
Apr 05We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease
Feb 23Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected
Dec 23Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Aug 26These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well
Feb 07Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors
Oct 24Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Aug 25Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?
Jul 19A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Apr 28Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly
Mar 14I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut
Feb 06Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Dec 13Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50
Oct 31Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching
Sep 22Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?
Sep 08Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?
Aug 26Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet
Jul 07Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?
Jun 14Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?
May 15Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 10Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 11Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?
Feb 24The Ajanta Pharma (NSE:AJANTPHARM) Share Price Is Up 56% And Shareholders Are Holding On
Jan 30
What Can We Make Of Ajanta Pharma's (NSE:AJANTPHARM) CEO Compensation?
Jan 18Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)
Jan 06What Percentage Of Ajanta Pharma Limited (NSE:AJANTPHARM) Shares Do Insiders Own?
Dec 25Opbrengsten en kosten
Hoe Ajanta Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 43,326 | 8,538 | 9,828 | 0 |
| 31 Mar 24 | 42,087 | 8,162 | 9,122 | 0 |
| 31 Dec 23 | 40,365 | 7,357 | 9,031 | 0 |
| 30 Sep 23 | 39,031 | 6,602 | 8,642 | 0 |
| 30 Jun 23 | 38,128 | 6,215 | 8,280 | 0 |
| 31 Mar 23 | 37,426 | 5,880 | 7,978 | 0 |
| 31 Dec 22 | 37,311 | 6,169 | 7,383 | 0 |
| 30 Sep 22 | 35,972 | 6,742 | 7,081 | 0 |
| 30 Jun 22 | 35,439 | 7,136 | 6,821 | 0 |
| 31 Mar 22 | 33,410 | 7,127 | 6,571 | 0 |
| 31 Dec 21 | 32,275 | 7,207 | 6,301 | 0 |
| 30 Sep 21 | 31,384 | 7,056 | 6,041 | 0 |
| 30 Jun 21 | 29,695 | 6,799 | 5,745 | 0 |
| 31 Mar 21 | 28,897 | 6,539 | 5,523 | 0 |
| 31 Dec 20 | 28,148 | 6,238 | 5,354 | 0 |
| 30 Sep 20 | 27,173 | 5,547 | 5,196 | 0 |
| 30 Jun 20 | 26,441 | 5,008 | 5,065 | 0 |
| 31 Mar 20 | 25,879 | 4,677 | 4,890 | 0 |
| 31 Dec 19 | 24,211 | 4,274 | 4,831 | 0 |
| 30 Sep 19 | 22,550 | 3,868 | 4,755 | 0 |
| 30 Jun 19 | 21,563 | 3,958 | 4,639 | 0 |
| 31 Mar 19 | 20,554 | 3,870 | 4,503 | 0 |
| 31 Dec 18 | 20,654 | 3,926 | 4,428 | 0 |
| 30 Sep 18 | 21,674 | 4,731 | 4,252 | 0 |
| 30 Jun 18 | 21,636 | 4,796 | 4,089 | 0 |
| 31 Mar 18 | 21,258 | 4,686 | 3,908 | 0 |
| 31 Dec 17 | 20,590 | 4,882 | 3,574 | 0 |
| 30 Sep 17 | 20,050 | 4,833 | 3,397 | 0 |
| 30 Jun 17 | 19,805 | 4,821 | 3,224 | 0 |
| 31 Mar 17 | 19,833 | 5,068 | 3,060 | 0 |
| 31 Dec 16 | 19,386 | 4,908 | 3,097 | 0 |
| 30 Sep 16 | 18,821 | 4,622 | 2,971 | 0 |
| 30 Jun 16 | 18,072 | 4,350 | 2,886 | 0 |
| 31 Mar 16 | 17,340 | 4,156 | 2,773 | 0 |
| 31 Dec 15 | 16,809 | 3,692 | 5,446 | 0 |
| 30 Sep 15 | 16,160 | 3,510 | 5,318 | 0 |
| 30 Jun 15 | 15,502 | 3,340 | 5,158 | 0 |
| 31 Mar 15 | 14,736 | 3,099 | 2,167 | 0 |
| 31 Mar 14 | 12,083 | 2,339 | 4,096 | 0 |
Kwaliteitswinsten: AJANTPHARM heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (19.7%) AJANTPHARM } zijn hoger dan vorig jaar (16.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van AJANTPHARM is de afgelopen 5 jaar met 11% per jaar gegroeid.
Versnelling van de groei: De winstgroei van AJANTPHARM over het afgelopen jaar ( 37.4% ) overtreft het 5-jarig gemiddelde ( 11% per jaar).
Winst versus industrie: De winstgroei AJANTPHARM over het afgelopen jaar ( 37.4% ) overtrof de Pharmaceuticals -sector 19.2%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 23.9% ) van AJANTPHARM wordt als hoog beschouwd.